SLC16A1 mRNA (Figure 10—figure supplement 1A), encoding MCT1, and SLC16A3 mRNA (Figure 10—figure supplement 2A), encoding MCT4, both showed high expression levels in basal-like breast cancer characterized by high proliferative (Figure 9—figure supplement 1D) and glycolytic (Figure 9—figure supplement 1E) activity. Here, SLC16A3 is linked to breast carcinoma.